Last quarter (Q3 2023), Armata Pharmaceuticals's total revenue was $1.23M, an increase of Infinity% from the same quarter last year. In Q3, Armata Pharmaceuticals's net income was $-31.16M. See Armata Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 2.33M	$ 5.51M	$ 4.47M	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 1.23M	-	-	-	-	-
Operating Expense	$ 22.93M	$ -42.45M	$ -28.30M	$ 21.59M	$ 19.09M	$ 10.59M
Operating Income	$ -44.47M	$ -42.45M	$ -28.30M	$ -21.59M	$ -19.09M	$ -10.59M
Net Non Operating Interest Income Expense	$ -1.05M	$ 29.00K	$ -95.00K	$ -600.00K	$ -835.00K	-
Other Income Expense	$ -6.28M	$ -5.51M	$ -5.20M	$ 6.00K	$ 445.00K	$ -1.84M
Pretax Income	$ -43.62M	$ -36.92M	$ -23.19M	$ -22.18M	$ -19.48M	$ -12.44M
Tax Provision	-	-	-	-	-	$ -328.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -59.45M	$ -36.92M	$ -23.19M	$ -22.18M	$ -19.48M	$ -12.11M
Basic EPS	$ -1.64	$ -1.08	$ -0.96	$ -1.35	$ -2.49	$ -8.96
Diluted EPS	$ -1.71	$ -1.08	$ -0.96	$ -1.35	$ -2.55	$ -8.96
Basic Average Shares	$ 142.49M	$ 34.29M	$ 24.10M	$ 16.42M	$ 7.83M	$ 1.36M
Diluted Average Shares	$ 162.97M	$ 34.29M	$ 24.10M	$ 16.42M	$ 8.01M	$ 1.36M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 22.93M	$ -42.45M	$ -28.30M	$ 21.59M	$ 19.09M	$ 10.59M
Net Income From Continuing And Discontinued Operation	$ -59.45M	$ -36.92M	$ -23.19M	$ -22.18M	$ -19.48M	$ -12.11M
Normalized Income	$ -20.95M	-	-	$ -22.18M	$ -19.93M	$ -10.32M
Interest Expense	-	-	-	$ 628.00K	$ 931.00K	-
EBIT	$ -42.46M	$ -36.92M	$ -23.09M	$ -21.55M	$ -18.55M	$ -10.59M
EBITDA	$ -41.48M	$ -36.02M	$ -21.89M	$ -20.44M	$ -17.20M	$ -10.21M

Currency in USD

Armata Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing